The way to monetize pre-approval would be a legit revenue generating partnership with L in a different indication or with Direct.
There are likely quite a few deals NWBO could cut that would add legitimacy to the company and help out the SP and give one or more BPs a financial stake in making DCVax succeed rather than have a neutral perspective or even a stake in seeing it fail as is currently the case.
Obviously successfully leveraging programs like HE and Right to Try (AKA Right to Die) would have been another way but they turned out to be wild goose chases.
I don't think a Advent/NWBO combination makes sense. It is not typical to have a merger between a CDMO and a biopharma company. They usually keep their distance. A CDMO (such as Advent) will have clients other than NWBO. If said CDMO was owned by NWBO but manufacturing for other drug companies (and potential competitors) that would be a huge conflict of interest and a red flag. Any business other than NWBO would search out a new CDMO. It doesn't make sense for a CDMO to tie themselves to a single company. all imo